Importantly, HAVCR1 has huge prospects as a potential target of immune checkpoint blockade therapy in Liver hepatocellular carcinoma and Pancreatic adenocarcinoma patients. The gene discussed is HAVCR1; the disease is pancreatic adenocarcinoma.